JOURNAL ARTICLE
REVIEW
Add like
Add dislike
Add to saved papers

Endoscopic surveillance or ablation for Barrett's esophagus?

The incidence of esophageal adenocarcinoma (EAC) is rising and the only known precursor of this disease is Barrett's esophagus (BE). EAC mortality remains high, prompting strategies to screen individuals with gastroesophageal reflux disease (GERD) symptoms to identify BE and conduct surveillance in order to detect neoplasia at a stage that is amenable to cure. The effectiveness of endoscopic eradication therapy has been improving with reduced harms, yet it is unclear which patients will benefit from this procedure. This chapter reviews the evidence supporting surveillance for BE to reduce mortality from EAC and combines these results with economic analyses to identify the optimal means to manage patients with BE with high-grade dysplasia, low-grade dysplasia, or no dysplasia.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app